Core Viewpoint - Goldman Sachs analyst James Schneider maintains a Buy rating on Verizon Communications Inc with a price target of $52, despite mixed results in subscriber metrics [1][5]. Financial Performance - Verizon reported total revenue of $33.5 billion, aligning with analyst estimates of $33.4 billion and the Street's estimate of $33.3 billion [1]. - Adjusted EPS was $1.19, surpassing the analyst estimate of $1.14 and the consensus of $1.15 [1]. - Total wireless service revenue reached $20.8 billion, reflecting a year-over-year increase of 2.7%, consistent with analyst estimates of $20.83 billion and above the Street's estimate of $20.44 billion [1]. Subscriber Metrics - Postpaid phone net additions were -289k, significantly below the analyst estimate of -240k and the Street's estimate of -199k [2]. - Consumer revenue was $25.6 billion, matching analyst estimates of $25.56 billion and the Street's estimate of $25.45 billion [2]. - Consumer postpaid phone net additions were -356k, underperforming against the analyst estimate of -320k and the Street's estimate of -289k [2]. - Consumer fixed wireless net additions were +199k, in line with the analyst estimate of +200k and the Street's estimate of +195k [2]. Business Outlook - Verizon reiterated its financial guidance for 2025, projecting wireless service revenue growth of 2%-2.8%, which translates to $83.7-$84.4 billion, compared to the analyst estimate of $84.2 billion and the Street's estimate of $82.8 billion [4]. - Adjusted EPS growth guidance is set at 0%-3%, implying a range of $4.59-$4.73, compared to the analyst and Street estimate of $4.68 [4]. Market Reaction - Verizon stock increased by 1.12% to $43.44 at the time of publication [7].

Core Insights - Ipsen reported strong sales growth for Q1 2025, with total sales reaching €918.8 million, reflecting an increase of 11.7% as reported and 11.6% at constant exchange rates (CER) [2][7] - The company highlighted significant growth in its Rare Disease segment, which saw a remarkable increase of 78.4% in sales, driven by innovative medicines [2][7] - Ipsen confirmed its full-year financial guidance for 2025, acknowledging potential negative impacts on Somatuline sales due to increased generic competition [3][7] Sales Performance - Oncology sales amounted to €655.0 million, up 8.5% [2] - Neuroscience sales reached €193.5 million, reflecting an 8.0% increase [2] - Rare Disease sales were €70.3 million, marking a substantial growth of 78.4% [2] Strategic Initiatives - The CEO emphasized the ongoing transformation of the company and the importance of 2025 for Ipsen, with multiple product launches and milestones expected [2] - Ipsen is advancing its pipeline with the regulatory filing for tovorafenib accepted by EMA for pediatric low-grade glioma, indicating a commitment to innovation in challenging cancer treatments [4][5] Financial Guidance - Ipsen confirmed its financial guidance for 2025, which includes anticipated challenges from generic competition affecting Somatuline sales [3] - The company expects total sales growth to exceed 5.0% at constant currency, with a core operating margin greater than 30.0% [8] Upcoming Milestones - Key milestones anticipated in 2025 include regulatory decisions for Cabometyx and fidrisertib, as well as proof-of-concept data for LANT [9] - The company initiated Phase I trials for IPN01195, a RAF inhibitor, complementing its existing pipeline [5] Refinancing Activities - Ipsen successfully completed its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, which is part of its refinancing strategy [10]